Role of GLP-1 in type 2 diabetes remission after gastric bypass surgery

Dr. Blandine Laferrère

Gastric bypass results in exaggerated release of the incretin hormone GLP-1 during meals. GLP-1 is a key hormone regulating insulin secretion and may play a role in the remission of type 2 diabetes after gastric bypass. This project focuses on the effect of GLP-1 on insulin secretion after gastric bypass in persons with type 2 diabetes. Clinicaltrial.gov # NCT02287285.

Efficacy of Sitagliptin as treatment of persistent or relapsing type 2 diabetes after gastric bypass surgery

Dr. Blandine Laferrère

Although type 2 diabetes goes into remission in ~60% of cases after gastric bypass surgery, some patients don’t experience full remission and / or experience a relapse in the years after the surgery. Treatment of type 2 diabetes after gastric bypass can be a challenge, because of dumping, risk of hypoglycemia and weight regain. This short randomized control trial tests the effect of sitagliptin, a DPP-4 inhibitor, in patients with relapsing or persistent type 2 diabetes after gastric bypass. Clinicaltrial.gov # NCT01512797